Based in Sheffield, UK, ELAROS 24/7 Limited is a digital health company specialising in the development of software solutions that support patients, clinicians and researchers. Founded in 2010, the company operates at the intersection of healthcare, technology and research, with a strong focus on improving patient outcomes through user-centred design and collaboration with healthcare systems such as the NHS in the UK, but also in Australia and Ireland.
The company specialises in the development of digital health tools aimed at improving patient care, clinical research and healthcare system efficiency. Their solutions typically include mobile apps and web-based clinical/research platforms that support patient engagement, remote monitoring and data collection in clinical studies. These tools are co-designed with patients and healthcare professionals to ensure usability and relevance. They are used across different therapeutic areas to capture patient-reported outcomes, facilitate communication between patients and clinicians and streamline clinical workflows.
As a MammoScreen Project partner, ELAROS plays a key role in ensuring that technical innovation is not only scientifically robust but also meaningful and accessible to patients. Their main contributions to the project are the Lite App, a digital tool designed to inform, engage and empower women in understanding breast cancer and screening options, and the Clinical Portal, a web-based platform designed to support healthcare professionals reviewing, organising and contextualising the results obtained within the project´s clinical study.
A distinctive strength of ELAROS is its commitment to co-creation. The company works closely with patients, clinicians and researchers to design solutions that reflect real needs. In the MammoScreen Project, this approach has been central to shaping the app and related tools that gather insights into women’s experiences, needs and concerns – such as the hereditary breast cancer questionnaire developed by the patient Association EVITA.
ELAROS has also led Patient and Public Involvement and Engagement (PPIE) activities within the MammoScreen Project. Through workshops and collaborative sessions, they have actively involved women and patient advocates in the design and refinement of the app, ensuring it is intuitive, relevant and trustworthy.
Beyond the technical aspects, ELAROS helps to bridge the gap between research and real-world use, one of the core aims of the MammoScreen Project. By translating complex scientific concepts into accessible information, they help build understanding and trust among future users of the MammoWave® technology.
As MammoScreen approaches its final phase, ELAROS’ work is especially valuable. Their digital solutions help ensure that the project’s outcomes are not only clinically effective, but also visible, understandable and usable by the people who most benefit from them: women.